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ril 1, 2013.he aim of this study was to assess the safety and efﬁcacy of the implantation of Resolute zotarolimus-eluting
stents (ZES) (Medtronic Inc., Santa Rosa, California) and Xience V everolimus-eluting stents (EES) (Abbott Vascular,
Santa Clara, California) following strict discontinuation of dual antiplatelet therapy (DAPT) after 12 months.Background Only limited long-term follow-up data are available from head-to-head comparisons of second-generation
drug-eluting stents.Methods The randomized TWENTE (The Real-World Endeavor Resolute Versus Xience V Drug-Eluting Stent Study in Twente)
trial is an investigator-initiated study performed in a population with many complex patients and lesions and only
limited exclusion criteria. Patients were randomly assigned 1:1 to ZES (n ¼ 697) or EES (n ¼ 694).Results Two-year follow-up information was available on all patients. The rate of continuation of DAPT beyond 12 months
was very low (5.4%). The primary endpoint of target vessel failure, a composite of cardiac death, target vessel–
related myocardial infarction, and target vessel revascularization, did not differ between ZES and EES (10.8% vs.
11.6, p ¼ 0.65), despite fewer target lesion revascularizations in patients with EES (2.6% vs. 4.9%, p ¼ 0.03). The
patient-oriented composite endpoint was similar (16.4% vs. 17.1%, p ¼ 0.75). Two-year rates of deﬁnite or probable
stent thrombosis were 1.2% and 1.4%, respectively (p ¼ 0.63). Very late deﬁnite or probable stent thrombosis
occurred only in 2 patients in each study arm (0.3% vs. 0.3%, p ¼ 1.00).Conclusions After 2 years of follow-up and stringent discontinuation of DAPT beyond 12 months, Resolute ZES and Xience V EES
showed similar results in terms of safety and efﬁcacy for treating patients with a majority of complex lesions and
off-label indications for drug-eluting stents. (The Real-World Endeavor Resolute Versus Xience V Drug-Eluting
Stent Study in Twente [TWENTE]; NCT01066650) (J Am Coll Cardiol 2013;61:2406–16) ª 2013 by the American
College of Cardiology FoundationSecond-generation drug-eluting stents (DES) such as the
Xience V everolimus-eluting stent (EES) (Abbott Vascular,
Santa Clara, California) and the Resolute zotarolimus-
eluting stent (ZES) (Medtronic Inc., Santa Rosa, Cal-
ifornia) were developed to improve clinical outcome by
overcoming the limitations of ﬁrst-generation DES (1,2).
The TWENTE (The Real-World Endeavor Resolute
Versus Xience V Drug-Eluting Stent Study in Twente) trial is
an investigator-initiated randomized study designed to
compare the safety and efﬁcacy of Resolute ZES with that of
Xience V EES in a large patient population with complex
coronary artery disease (3). This patient population reﬂects
routine clinical practice, as has recently been demonstrated
by the ﬁndings of a study of eligible nonenrolled patients (4).
In the TWENTE trial, the rates of the primary endpoint of
target vessel failure (TVF), a composite of cardiac death,edtronic. The research department of Thor-
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3; revised manuscript received March 14, 2013,target vessel–related myocardial infarction (MI), and clini-
cally indicated target vessel revascularization (TVR), at 1
year were favorable and similar for Resolute ZES and Xience
V EES. In addition, both stents did not signiﬁcantly differ
in the rates of several other secondary endpoints, such as
stent thrombosis and a patient-oriented composite endpoint.
Only a few long-term data have been reported from
randomized trials that compared second-generation DES in
routine clinical practice. Although long-term data are avail-
able for the Xience V EES from several comparative studies
of DES (5–8), only a single randomized study reported
long-term outcome with the Resolute ZES (9). In addition,
there is even less knowledge of the clinical performance
of these DES after discontinuation of stringent dual anti-
platelet therapy (DAPT) at 12 months. Use of DAPT was
continued beyond 1 year in 13% to 69% of patients in
previous comparative trials of DES (5,8,10). In the
TWENTE trial, however, a strict policy of discontinuation
of DAPT after 12 months was followed, which is of interest
for the present pre-speciﬁed 2-year analysis of clinical
outcomes.
Methods
Study design and patient population. The TWENTE trial
has previously been described in detail (3,11). In brief, the
Figure 1 Study Flow Diagr
A total of 1,391 patients were enro
(n ¼ 694). DES ¼ drug-eluting sten
Abbreviations
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DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
EES = everolimus-eluting
stent(s)
MI = myocardial infarction
PCI = percutaneous coronary
intervention
TLF = target lesion failure
TLR = target lesion
revascularization
TVF = target vessel failure
TVR = target vessel
revascularization
ZES = zotarolimus-eluting
stent(s)
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initiated, patient-blinded, ran-
domized, comparative trial ofDES
with limited exclusion criteria in
a real-world study population
with a majority of complex lesions
and off-label indications forDES.
Study enrollment was performed
between June 2008 and August
2010 at Thoraxcentrum Twente
in Enschede, the Netherlands.
Patients capable of providing
informed consent with an indi-
cation for percutaneous coronary
intervention (PCI) with DES
were randomized to treatment
with Resolute or Xience V stents
in a 1:1 ratio. There was no limit
for lesion length, reference vesselsize, and number of target lesions or vessels. The main
exclusion criterion was a recent ST-segment elevation
MI. The study was approved by the institutional ethics
committee and complied with the Declaration of Helsinki.
All patients provided written informed consent.am
lled in the TWENTE trial. These were randomized to z
t(s); PCI ¼ percutaneous coronary intervention.Intervention, medication, and in-hospital course. Patients
were pre-treated with acetylsalicylic acid and clopidogrel. At
discharge, the combination of acetylsalicylic acid 100 mg once
daily indeﬁnitely and clopidogrel 75 mg once daily for
12 months was prescribed. Use of DAPT was determined by
patient questionnaire and/or information from each patient’s
general practitioner or pharmacy. Lesion pre-dilation, direct
stenting, stent post-dilation, and/or use of glycoprotein
IIb/IIIa antagonists were permitted at the operators’ discre-
tion. Liberal use of post-dilation was encouraged. Cardiac
biomarkers and electrocardiograms were systematically
assessed in all patients before and after PCI to identify
periprocedural MI.
Deﬁnitions of clinical endpoints. Deﬁnitions of all clin-
ical endpoints have previously been described in detail (3).
The primary clinical endpoint was the incidence of TVF at
1 year, a composite endpoint that was deﬁned as cardiac death,
target vessel–related MI (or not attributable to a nontarget
vessel), and clinically driven TVR.The pre-speciﬁed secondary
endpoints included TVF at 2-year follow-up, all-cause
mortality, stent thrombosis, target lesion failure (TLF), major
adverse cardiac events, and a patient-oriented composite
endpoint consisting of all-cause mortality, any MI, and any
repeat revascularization. All clinical endpoints, including stentotarlolimus-eluting Resolute stents (n ¼ 697) or everolimus-eluting Xience V stents
Table 1 Baseline Characteristics of Patients
Variable
Total Population
(N ¼ 1,391)
Resolute ZES
(n ¼ 697)
Xience V SES
(n ¼ 694) p Value
Age (yrs) 64.2  10.8 63.9  10.9 64.5  10.7 0.32
Men 1009 (72.5) 505 (72.5) 504 (72.6) 0.94
Diabetes mellitus (any) 301 (21.6) 158 (22.7) 143 (20.6) 0.35
Chronic renal failure* 38 (2.7) 19 (2.7) 19 (2.7) 0.99
Arterial hypertension 773 (55.6) 386 (55.4) 387 (55.8) 0.89
Hypercholesterolemia 803/1,357 (59.2) 392/688 (57.0) 411/669 (61.4) 0.10
Current smoker 340 (24.4) 176 (25.3) 164 (23.6) 0.48
Family history of coronary artery disease 740/1,309 (53.2) 370/660 (53.1) 370/649 (53.3) 0.73
Previous myocardial infarction (any) 450 (32.4) 213 (30.6) 237 (34.1) 0.15
Previous percutaneous coronary intervention 288 (20.7) 139 (19.9) 149 (21.5) 0.48
Previous coronary artery bypass grafting 148 (10.6) 68 (9.8) 80 (11.5) 0.28
Stable angina pectoris 674 (48.5) 335 (48.1) 339 (48.8) 0.47
Acute coronary syndrome 717 (51.5) 362 (51.9) 355 (51.2) 0.47
Unstable angina 325 (23.4) 172 (24.7) 153 (22.0) 0.47
Non–ST-elevation myocardial infarction 392 (28.2) 190 (27.3) 202 (29.1) 0.47
Multivessel treatment 336 (24.2) 174 (25.0) 162 (23.3) 0.48
Total number of lesions treated per patient 0.49
1 857 (61.6) 422 (60.5) 434 (62.7)
2 393 (28.3) 198 (28.4) 195 (28.1)
3 or more 141 (10.1) 77 (11.0) 64 (9.2)
At least one off-label indicationy 1,077 (77.4) 547 (78.5) 530 (76.4) 0.35
Total number of lesions treated 2,116 1,080 1,036
Number of stents implanted per lesion 1.33  0.62 1.31  0.59 1.35  0.64 0.09
Total stent length per lesion (mm) 26.9  15.69 27.00  15.39 26.85  16.00 0.83
Direct stenting 824 (38.9) 416 (38.5) 408 (39.4) 0.68
ACC/AHA lesion class 0.90
A 154 (7.3) 77 (7.1) 77(7.5)
B1 478 (22.6) 241 (22.3) 237 (22.9)
B2 678 (32.0) 342 (31.7) 336 (32.4)
C 806 (38.1) 420 (38.9) 386 (37.3)
Bifurcated lesion 518 (24.5) 258 (23.9) 260 (25.1) 0.59
Thrombus presentz 71 (3.4) 33 (3.1) 38 (3.7) 0.43
Chronic total occlusion 100 (4.7) 53 (4.9) 47 (4.5) 0.69
Values are n (%) or mean  SD. *Chronic renal failure was deﬁned as a serum creatinine level 130 mmol/l. yOff-label stent use included renal insufﬁciency, an ejection fraction <30%, the occurrence of
acute myocardial infarction within the previous 72 h, more than one lesion per vessel, at least 2 vessels with stents, a lesion measuring more than 27 mm, bifurcation, bypass grafts, in-stent restenosis,
unprotected left main artery, lesions with thrombus, or total occlusion. zThrombus triggering use of thrombus aspiration catheters.
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association.
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2409thrombosis, were deﬁned according to the Academic Research
Consortium, including the addendum to the/? deﬁnition of
MI (12,13).
Acquisition and analysis of clinical data. Clinical follow-up
data were obtained at visits to outpatient clinics or, if not
feasible, by telephone follow-up and/or medical questionnaire.
Follow-up data were available in all but 4 patients, who
withdrew informed consent during the course of the study
(2 patients in the Resolute ZES group and 2 patients in the
Xience V EES group). Processing of clinical data and
adjudication of all adverse clinical events were performed by
an independent external contract research organization
(Cardialysis, Rotterdam, the Netherlands). Analyses were
performed on the basis of the principle of intention-to-treat.
Statistical analysis. Statistical analyses were performed
with SPSS version 15.0 (SPSS Inc., Chicago, Illinois).
Categorical variables were assessed with the chi-square test or
Fisher exact test as appropriate, whereas continuous variableswere assessed with the Wilcoxon rank sum test or Student t
test as appropriate. The times to the primary endpoint and to
the components thereof were assessed according to the
Kaplan-Meier method, and the log-rank test was applied to
compare the 2 groups. A landmark analysis was performed at
1 year for various events. For each type of event, patients were
excluded from the landmark analysis if the speciﬁc event or
death occurred in the ﬁrst year. Unless otherwise speciﬁed, p
values and conﬁdence intervals were 2 sided. A p value<0.05
was considered signiﬁcant.
Results
A total of 1,391 patients were randomized to treatment with
Resolute ZES (n ¼ 697) or Xience V EES (n ¼ 694). Apart
from 4 patients who withdrew their consent during the
ﬁrst year of follow-up, 2-year follow-up information was
obtained from all patients (Fig. 1). Baseline clinical,
Table 2 Two-Year Clinical Outcomes
Resolute ZES
(n ¼ 695)
Xience V EES
(n ¼ 692)
Difference
(95% Conﬁdence Interval) p Value
Target vessel failure 75 (10.8) 80 (11.6) 0.8 (4.1 to 2.6) 0.65
Death
Any cause 29 (4.2) 33 (4.8) 0.6 (2.8 to 1.6) 0.59
Cardiac cause 11 (1.6) 19 (2.7) 1.2 (2.7 to 0.4) 0.14
Target vessel–related myocardial infarction
Any 37 (5.3) 39 (5.6) 0.3 (2.7 to 2.1) 0.80
Q-wave 8 (1.2) 9 (1.3) 0.2 (1.3 to 1.0) 0.80
Non–Q-wave 29 (4.2) 30 (4.3) 0.2 (2.3 to 2.0) 0.88
Clinically indicated target vessel revascularization
Any 39 (5.6) 35 (5.1) 0.6 (1.8 to 2.9) 0.65
Percutaneous 32 (4.6) 28 (4.0) 0.6 (1.6 to 2.7) 0.61
Surgical 8 (1.2) 8 (1.2) 0.0 (1.1 to 1.1) 0.99
Target lesion failure 73 (10.5) 68 (9.8) 0.7 (2.5 to 3.9) 0.68
Clinically indicated target lesion revascularization
Any 34 (4.9) 18 (2.6) 2.3 (0.3 to 4.3) 0.03
Percutaneous 28 (4.0) 13 (1.9) 2.2 (0.4 to 3.9) 0.02
Surgical 7 (1.0) 6 (0.9) 0.1 (0.9 to 1.2) 0.79
Death from cardiac causes or target vessel myocardial infarction 46 (6.6) 53 (7.7) 1.0 (3.8 to 1.7) 0.45
Major adverse cardiac events* 90 (12.9) 82 (11.8) 1.1 (2.4 to 4.6) 0.53
Patient-oriented composite endpointy 114 (16.4) 118 (17.1) 0.7 (4.6 to 3.3) 0.75
Stent thrombosis
Deﬁnite (0–720 days) 6 (0.9) 1 (0.1) 0.7 (0.0 to 1.5) 0.12
Deﬁnite or probable (0–720 days) 8 (1.2) 10 (1.4) 0.3 (1.5 to 0.9) 0.63
Deﬁnite, probable, or possible (0–720 days) 14 (2.0) 20 (2.9) 0.9 (2.5 to 0.8) 0.29
Very late deﬁnite or probable (361–720 days) 2 (0.3) 2 (0.3) 0 (0.6 to 0.6) 1.00
Values are n (%). *Major adverse cardiac events is a composite of all-cause death, any myocardial infarction, emergent coronary artery bypass surgery, and clinically indicated target lesion revascularization.
yPatient-oriented composite endpoint is a composite endpoint of all-cause death, any myocardial infarction, and any revascularization.
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2410angiographic, and procedural characteristics of all study
patients are summarized in Table 1.
At 2-year follow-up, the composite primary endpoint of
TVF occurred in 75 patients (10.8%) in the Resolute ZES
group and in 80 patients (11.6%) in the Xience V EES group
and did not differ signiﬁcantly between groups (absolute
difference: 0.8 [4.1 to 2.6]; p ¼ 0.65) (Table 2, Fig. 2).
The patient-oriented composite endpoint rates were also
similar for patients treated with ZES and EES; this endpoint
occurred in 114 patients (16.4%) versus 118 patients (17.1%),
respectively. For the individual components of the composite
primary endpoint of TVFdcardiac death (1.6% vs. 2.7%,
p ¼ 0.14), target vessel–related MI (5.3% vs. 5.6%, p ¼
0.80), and clinically driven TVR (5.6% vs. 5.1%, p¼ 0.65)d
there was also no signiﬁcant difference at 2 years. The results
of an exploratory subgroup analysis at 2-year follow-up with
regard to TVF are shown in Figure 3. The subgroup analysis
showed consistent results across different subgroups.
Compared with Resolute ZES, the use of Xience V EES was
associated with a lower rate of clinically indicated target
lesion revascularization (TLR) (4.9% vs. 2.6%, p ¼ 0.03),
but this did not result in a signiﬁcant difference in the
device-oriented composite endpoint of TLF (10.5% vs.
9.8%, p ¼ 0.68).
Table 3 shows the difference in outcome between 1-year
and 2-year follow-up. No signiﬁcant difference was observedfor various endpoints. However, there were numerically
more cardiac deaths among patients in the Xience V EES
group (0.6% vs. 1.3%, p ¼ 0.16) and numerically more
clinically indicated cases of TLR in the Resolute ZES group
(2.3% vs. 1.2%, p ¼ 0.13).
In accordance with national and European guidelines,
the per-protocol duration of DAPT was 1 year after
PCI. Table 4 presents data on the actual use of DAPT.
DAPT was discontinued after 1 year or less in 635 patients
(93.4%) in the Resolute ZES group and 650 patients
(95.9%) in the Xience V EES group. Of all patients,
73 (5.4%) continued DAPT beyond 12 months. At 2-year
follow-up, 51 patients (7.7%) in the Resolute ZES group
and 40 patients (6.2%) in the Xience V EES group were
still on DAPT.
The rates of ARC-deﬁned deﬁnite stent thrombosis
(0.9% vs. 0.1%, p ¼ 0.12) and deﬁnite or probable stent
thrombosis (1.2% vs. 1.4%, p ¼ 0.63) at 2-year follow-up
were low and similar for both Resolute ZES and Xience V
EES (Fig. 4). Very late deﬁnite or probable stent throm-
bosis was seen in 2 patients in both study arms (0.3% vs.
0.3%, p ¼ 1.00), resulting in an MI in all 4 cases (Table 5).
Of the 14 patients with deﬁnite or probable stent throm-
bosis in the ﬁrst year of follow-up, 11 (78.6%) were on
DAPT. All 4 patients with very late deﬁnite or probable
stent thrombosis were on acetylsalicylic acid monotherapy
Figure 2 Kaplan-Meier for Primary Endpoint and the Individual Components of the Primary Endpoint
Kaplan-Meier cumulative incidence curves at 2 years for the primary endpoint, a composite of cardiac death, target vessel–related myocardial infarction, and target vessel
revascularization (A); cardiac death (B); myocardial infarction (C); and target vessel revascularization (D) for the zotarolimus-eluting Resolute stent and the everolimus-eluting
Xience V stent.
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2411beyond 1 year and there was no clear relation between stent
thrombosis and discontinuation of DAPT, with a period of
at least 79 days between very late stent thrombosis and
discontinuation of DAPT.
Discussion
At the 2-year follow-up of the TWENTE trial, which fol-
lowed a stringent approach of discontinuation of DAPT
after 12 months, Resolute ZES and Xience V EES showed
similar and beneﬁcial results in terms of safety and efﬁcacy
for treating real-world patients who underwent PCI with
a vast majority of complex lesions and off-label indications
for use of DES. Both study arms showed similar rates of
TVF and its components: cardiac death, target vessel–related
MI, and clinically indicated TVR. The absence of a differ-
ence in TVF at 2-year follow-up was consistent across
several subgroups. Despite a lower rate of clinically indicated
TLR in the Xience V EES group, there was no signiﬁcantdifference between groups in the device-oriented composite
endpoint of TLF and the more patient-oriented composite
clinical endpoints (major adverse cardiac events and patient-
oriented composite endpoint).
Resolute ZES and Xience V EES are both second-
generation DES that use cobalt-chromium stent platforms
and elute limus analogues from durable polymer-based
coatings with improved biocompatibility (14,15). This im-
provement in coating was considered desirable because the
limited biocompatibility of coatings on ﬁrst-generation DES
(16–18) was found to be associated with hypersensitivity and
local vascular inﬂammation that could induce intraluminal
thrombus formation (19–21).
In several randomized comparisons with ﬁrst-generation
DES, Xience V EES have demonstrated proven sustained
safety and efﬁcacy beyond 1 year, which has led to wide
acceptance in clinical practice. In SPIRIT IV (Clinical
Evaluation of the Xience V Everolimus Eluting Coronary
Stent System IV), treatment with Xience V EES was
Figure 3 Subgroup Analysis: Target Vessel Failure at 2 Years
Target vessel failure is a composite of cardiac death, target vessel myocardial infarction, and clinically driven target vessel revascularization. CI ¼ conﬁdence interval;
NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous coronary intervention.
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2412associated with a lower rate of TLF after 2 years (6.9% vs.
9.9%, p ¼ 0.003) compared with the paclitaxel-eluting
Taxus stent (Boston Scientiﬁc, Natick, Massachusetts) (8).
The superiority of Xience V EES over the Taxus stentTable 3 Outcome Differences Between 1 and 2 Y
Resolute ZWS
Target vessel failure 2.9 (18/631)
Death
Any cause 2.1 (14/680)
Cardiac cause 0.6 (4/680)
Target vessel–related myocardial infarction 0.8 (5/649)
Clinically indicated target vessel
revascularization
2.4 (16/657)
Target lesion failure 2.8 (18/633)
Clinically indicated target lesion
revascularization
2.3 (15/661)
Major adverse cardiac events* 4.5 (28/625)
Patient-oriented composite endpointy 6.0 (37/617)
Very late stent thrombosis (361–720 days)
Deﬁnite 0.3 (2/677)
Deﬁnite or probable 0.3 (2/677)
Deﬁnite, probable, or possible 0.6 (7/675)
Values are % (n/N) *Major adverse cardiac events is a composite of all-cau
surgery, and clinically indicated target lesion revascularization. yPatient-orien
myocardial infarction, and any revascularization.was also seen in the 2-year results of COMPARE (A Trial
of Everolimus-eluting Stents and Paclitaxel-eluting Stents
for Coronary Revascularization in Daily Practice), with TLF
rates of 7.4% versus 11.3% (p ¼ 0.004) (5). The results ofears
Xience V EES
Difference
(95% Conﬁdence Interval) p Value
3.8 (24/632) 0.9 (2.9 to 1.0) 0.35
2.8 (19/678) 0.7 (2.4 to 0.9) 0.37
1.3 (9/678) 0.7 (1.8 to 0.3) 0.16
1.1 (7/650) 0.3 (1.4 to 0.7) 0.56
2.4 (16/659) 0.00 (1.7 to 1.7) 0.99
3.3 (21/641) 0.4 (2.3 to 1.5) 0.65
1.2 (8/668) 1.1 (0.3 to 2.5) 0.13
4.9 (31/630) 0.4 (2.8 to 1.9) 0.71
7.4 (46/619) 1.4 (4.2 to 1.4) 0.31
0.1 (1/678) 0.2 (0.4 to 0.7) 0.62
0.3 (2/674) 0.00 (0.6 to 0.6) 1.00
1.5 (10/674) 0.9 (2.0 to 0.2) 0.11
se death, any myocardial infarction, emergent coronary artery bypass
ted composite endpoint is a composite endpoint of all-cause death, any
Table 4
Use of Acetylsalicylic Acid, Clopidogrel,
and Dual Antiplatelet Therapy
Resolute ZES Xience V EES p Value
At baseline n ¼ 697 n ¼ 694
Acetylsalicylic acid* 688 (98.7) 692 (99.7) 0.04
Clopidogrel 697 (100) 694 (100) 1.00
DAPT 688 (98.7) 692 (99.7) 0.04
At 1-year follow-up n ¼ 680 n ¼ 678
Acetylsalicylic acid 635 (93.4) 628 (92.6) 0.59
Clopidogrel 0.14
Stopped after 1 year 615 (90.4) 633 (93.4)
Less than 1 year 13 (1.9) 8 (1.2)
Continued after 1 year 52 (7.7) 37 (5.5)
DAPT 0.13
Stopped after 1 year 578 (85.0) 593 (87.5)
Less than 1 year 57 (8.4) 57 (8.4)
Continued after 1 year 45 (6.6) 28 (4.1)
At 2-year follow-up n ¼ 662 n ¼ 650
Acetylsalicylic acid 606 (91.5) 599 (92.2) 0.69
Clopidogrel 64 (9.7) 51 (7.8) 0.24
DAPT 51 (7.7) 40 (6.2) 0.27
Values are n (%). *No acetylsalicylic acid was used due to allergic reactions or concomitant use of
a vitamin K antagonist.
DAPT ¼ dual antiplatelet therapy (acetylsalicylic acid and clopidogrel).
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2413SORT OUT IV (Scandinavian Organization for Random-
ized Trials With Clinical Outcome IV) demonstrated that
Xience V EES had similar and low rates of TLF at 2-year
follow-up but showed noninferiority compared with the
ﬁrst-generation sirolimus-eluting stent Cyper Selectþ
(Cordis, Bridgewater, New Jersey) (6).Figure 4 Cumulative Incidence of Deﬁnite or Probable Stent Thromb
The cumulative incidence of deﬁnite or probable stent thrombosis in 2 years, according t
(acetylsalicylic acid and clopidogrel).Only a single randomized study, the RESOLUTE All
Comers trial, has reported long-term outcome data for
Resolute ZES. After 2 years, Resolute ZES were equivalent
to Xience V EES with regard to both TVF (12.6% vs.
12.2%, p ¼ 0.85) and the patient-oriented composite
endpoint (20.6% vs. 20.5%, p ¼ 0.96) (9).
The current 2-year data of the TWENTE trial gener-
ally support the ﬁndings of the RESOLUTE All Comers
trial and show that Resolute ZES have a long-term safety
proﬁle that is similar to that of Xience V EES, which was
previously shown to be superior to the Taxus stent in
SPIRIT IV and COMPARE (5,8). Although the rates of
TLR for Resolute ZES and Xience V EES were similar in
the RESOLUTE All Comers trial (5.7% and 5.1%, re-
spectively), in the TWENTE trial the rate of TLR for
Xience V EESwas particularly low, resulting in a statistically
signiﬁcant difference (4.9% vs. 2.6%, p ¼ 0.03). However,
this difference did not translate into a difference in the
device-oriented composite endpoint of TLF because of a
numerically higher cardiac death rate in the Xience V EES
group (1.4% vs. 2.6%, p ¼ 0.14). In fact, the Kaplan-Meier
cumulative event curves of cardiac death tend to diverge
after approximately 10 months, but a landmark analysis
revealed only a nonsigniﬁcant difference in cardiac death
during the second year of follow-up (0.6% vs.1.3%, p ¼ 0.16).
Nevertheless, these data suggest that assessment of this pa-
rameter beyond the present 2-year follow-up may be of interest.
At 2-year follow-up in the TWENTE trial, the rates of
2-year deﬁnite or probable stent thrombosis (1.2% vs. 1.4%)
and very late deﬁnite or probable stent thrombosis (0.3% for
both arms) were low for both Resolute ZES and Xience Vosis Over 2 Years
o the Academic Research Consortium deﬁnition. DAPT ¼ dual antiplatelet therapy
Table 5 Details on Deﬁnite or Probable Stent Thrombosis
Stent/
Thrombosis
Type
Indication
for PCI
Days to
Stent
Thrombosis
After PCI
Days After
Discontinuation
of DAPT
to Event
Target
Vessel
Clinical
Event
After Stent
Thrombosis
Use of
Antiplatelet
Therapy at
Event
Resolute
Probable Stable
angina
0 NA RCX, LAD MI On DAPT
(A þ C)
Deﬁnite Unstable
angina
5 NA LAD, RCA Death On DAPT
(A þ C)
Deﬁnite Stable
angina
54 NA RCA, LAD MI, TLR On DAPT
(A þ C)
Deﬁnite Stable
angina
205 NA RCX MI, TLR On DAPT
(A þ C)
Deﬁnite NSTEMI 245 245* RCA MI, TLR Off DAPT
(C þ VKA)
Probable Stable
angina
357 NA RCX MI On DAPT
(A þ C)
Deﬁnite Unstable
angina
563 198 RCA MI, TLR Off DAPT
(A)
Deﬁnite NSTEMI 715 351 RCA, LAD MI, TLR Off DAPT
(A)
Xience V
Probable NSTEMI 0 NA Vein
graft,
RCA
MI On DAPT
(A þ C þ VKA)
Probable Unstable
angina
0 NA RCA MI On DAPT
(A þ C)
Probable Stable
angina
1 NA RCX, LAD MI On DAPT
(A þ C)
Probable NSTEMI 3 NA LAD Death On DAPT
(A þ C)
Probable NSTEMI 5 NA RCA, LAD Death On DAPT
(A þ C)
Probable Stable
angina
8 NA RCX Death On DAPT
(A þ C)
Probable Unstable
angina
28 1 RCA MI Off DAPT
(C þ VKA)
Probable NSTEMI 136 136y LAD MI, death Off DAPT
(A)
Deﬁnite Stable
angina
444 79 RCX, LAD MI, thrombus
aspiration
Off DAPT
(A)
Probable Stable
angina
611 246 RCA TVR, MI Off DAPT
(A)
*From day 0 on therapy with VKA þ clopidogrel due to allergy for acetylsalicylic acid. yFrom day 0 only acetylsalicylic acid for an unknown reason.
A ¼ acetylsalicylic acid; C ¼ clopidogrel; DAPT ¼ dual antiplatelet therapy (acetylsalicylic acid and clopidogrel); LAD ¼ left anterior descending
coronary artery; MI ¼ myocardial infarction; NA ¼ not available; NSTEMI ¼ non–ST-segment elevation myocardial infarction; PCI ¼ percutaneous
coronary intervention; RCA ¼ right coronary artery; RCX ¼ ramus circumﬂex artery; TLR ¼ target lesion revascularization; TVR ¼ target vessel
revascularization; VKA ¼ vitamin K antagonist.
Tandjung et al. JACC Vol. 61, No. 24, 2013
The TWENTE 2-Year Outcome After 12 Months of DAPT June 18, 2013:2406–16
2414EES. These data are reassuring for Resolute ZES, consid-
ering that optical coherence tomography data had shown
more uncovered stent struts with Resolute ZES than with
Endeavor stents (22). The rates of stent thrombosis were
similar to those in the RESOLUTE All Comers trial
(2-year rate of deﬁnite or probable stent thrombosis, 1.9%
vs. 1.0%; 2-year rate of very late deﬁnite or probable stent
thrombosis, 0.3% vs. 0.3%) as well as the rates of stent
thrombosis for Xience V EES in SORT OUT IV and
COMPARE (5,6,9). In addition, the 2-year rates of deﬁnite
or probable stent thrombosis in the TWENTE trial weresimilar to the pooled 2-year rates of stent thrombosis in
SPIRIT II and III (1.2%), using Xience V EES in selected
patient populations with/? more stable coronary disease (23).
The 2-year rates of deﬁnite stent thrombosis in the
TWENTE trial were also low, showing a nonsigniﬁcant
trend toward a lower rate in the Xience V EES group
(p ¼ 0.12). Nevertheless, it may be difﬁcult to directly
compare rates of stent thrombosis from different trials,
because they could be inﬂuenced by differences in study
populations. In the TWENTE trial, just one of the overall
7 deﬁnite stent thromboses was lethal, while very late
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2415deﬁnite or probable stent thrombosis was not associated with
mortality. Similar ﬁndings were observed in other studies
evaluating second-generation DES (5,6,9). The overall low
rates of stent thrombosis and low rates of mortality associ-
ated with stent thrombosis in patients in the Resolute ZES
group were similar to those in patients in the Xience V EES
group, which has shown the lowest rates of stent thrombosis
in comparison to earlier-generation DES (24,25). The data
of the TWENTE trial underline the safety proﬁle of both
second-generation DES.
The low rates of very late stent thrombosis in the
TWENTE trial are particularly noteworthy considering the
low rate of continuation of DAPT beyond 12 months,
which was in accordance with current guidelines (26,27). In
fact, the rate of DAPT use at 2-year follow-up (6.9%) was
much lower than that of several European DES trials in all-
comer populations, such as LEADERS (23%) (10,28),
RESOLUTE All Comers (18%) (9), and COMPARE
(13%) (5), and some U.S. trials of DES in patients with
somewhat less complex coronary disease, such as SPIRIT IV
(69%) (8,29) and RESOLUTE US (67%) (30,31). In
addition, in the second year of follow-up after discontinuation
of DAPT, rate of deﬁnite or probable stent thrombosis was
lower compared with that with ﬁrst-generation DES, which
showed a deﬁnite and continuous risk of very late stent
thrombosis (32). Hence, the TWENTE trial provides
interesting safety information on stringent discontinuation
of DAPT at 1 year after PCI in a study population with
many complex patients and lesions treated with Resolute
ZES and Xience V EES.
Study limitations. This prospective, randomized, single-
center trial was performed in a high-volume tertiary care
center by experienced operators who applied relatively
uniformprocedural strategies. For that reason, generalizability
of the study results to other clinical settings may be limited. In
addition, conclusions do not apply to patients with ST-
segment elevation MI requiring primary PCI, because
this patient subset was not assessed in the TWENTE trial.
The subgroup analysis was not pre-speciﬁed. However, to
avoid any subjective post hoc selection, we used the same
subgroups as the RESOLUTE All Comers trial (33) and the
1-year analysis of the TWENTE trial (3).
Conclusions
After 2 years of follow-up and stringent discontinuation of
DAPT beyond 1 year, Resolute ZES and Xience V EES
showed similar results in terms of safety and efﬁcacy for
treating real-world patients with a majority of complex
lesions and off-label indications for DES.Reprint requests and correspondence: Prof. Clemens von
Birgelen, Department of Cardiology, Thoraxcentrum Twente,
Haaksbergerstraat 55, 7513ER Enschede, the Netherlands.
E-mail: c.vonbirgelen@mst.nl.REFERENCES
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